A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment

• Main Authors: Karthick Vishwanathan (Author), Inmaculada Sanchez‐Simon (Author), Bhumsuk Keam (Author), Nicolas Penel (Author), Maria deMiguel‐Luken (Author), Doris Weilert (Author), Andrew Mills (Author), Marcelo Marotti (Author), Martin Johnson (Author), Alain Ravaud (Author)
• Format: Book
• Published: Wiley, 2020-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Osimertinib is a third‐generation, irreversible, oral epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR‐TKI sensitizing and EGFR T790M and has demonstrated efficacy in non‐small cell lung cancer (NSCLC) central nervous s...